New Treatment - Brittle Bone Disease
New Treatment for Brittle Bone Disease Found
Aug. 9, 2013 — A new treatment for
children with brittle bone disease has been developed by the University of
Sheffield and Sheffield Children's Hospital.
The study of the new treatment for
children with the fragile bone disease Osteogenesis Imperfecta was
published this week in The Lancet.
This is the first study to clearly
demonstrate that the use of the medicine risedronate can not only reduce the risk of fracture in
children with brittle bones but also have rapid action -- the curves for
fracture risk begin to diverge after only 6 weeks of treatment.
Nick Bishop, Professor of Paediatric
Bone Disease at the University of Sheffield, said: "We wanted to show that
the use of risedronate
could significantly impact on children's lives by reducing fracture rates --
and it did.
"The fact that this medicine can be given by mouth at home
(other similar medicines are given by a drip in hospital) makes it
family-friendly."
The study, funded by the Alliance
for Better Bone Health, trialled
children with Osteogenesis Imperfecta aged 4-15 years and showed that oral risedronate reduced the
risk of first and recurrent clinical fractures and that the drug was generally
well tolerated.
Share this story on Facebook,
Twitter
No comments:
Post a Comment